Role of predictive biomarkers in patients with MIBC

Antonio Cigliola, MD, IRCCS San Raffaele Hospital, Milan, Italy, discusses predictive biomarkers to guide neoadjuvant therapies in muscle-invasive bladder cancer (MIBC). Patients who underwent radical cystectomy exhibited negative circulating tumor DNA (ctDNA) signatera test results. Among those achieving complete pathological response (pCR) to therapy, tumor samples revealed mutations in ARID1A and BRCA genes. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.